Agenda
Download 2024 Brochure
Flip through our 2024 conference brochure and discover what’s new this year.
- Jump to:
- At a Glance
- Day 1
- Day 2
- Print-friendly Format
Day 1 - Monday, February 12, 2024
Day 2 - Tuesday, February 13, 2024
Day 1 - Monday, February 12, 2024
7:45 |
Registration Opens and Continental Breakfast Served |
8:45 |
Opening Remarks from the Co-ChairsRosemarie Childerhose Dipti Tankala |
9:00 |
Negotiating with a New pCPA: What the Latest Changes to the Organization Mean for Manufacturers Moving ForwardDouglas Clark Moderator:Mark Smitheys |
9:45 |
CADTH’s New Time Limited Reimbursement Recommendation: Examining the Finer Points of the New Process and Projected Impact on Patient AccessSudha Kutty CADTH has introduced a new reimbursement recommendation category to address the unmet needs of those living with a rare or debilitating illness in Canada. The introduction of the time-limited recommendation follows consultations with industry and expert advisory committees. This is an opportunity for drug manufacturers to secure a recommendation for public funding on promising pharmaceuticals for a defined period of time, helping to expedite patient access, while more evidence is collected for a final reimbursement decision.
|
10:30 |
Morning Coffee and Networking Break |
11:00 |
How Manufacturers Can Strengthen RWE Submissions for Optimal Use in Regulatory and Reimbursement Decision MakingDr. Nicole Mittmann David Shum Moderator:Brad Millson
|
11:45 |
Examining International Examples of Early Access Pathways to Innovative Oncology DrugsTara Cowling
|
12:30 |
Networking Lunch |
1:30 |
PATHWAYS: Collaborating with Indigenous Leaders and Communities to Help Close the Healthcare Gap and Strive for Health EquityRoger Chai Allison Deer Keith Leclaire This session will share the PATHWAYS journey to create a culturally sensitive, Indigenous-informed and collaborative framework to address healthcare gaps in Indigenous communities in Canada. Key points to be covered, include:
|
2:15 |
Patient Inclusivity: How to Integrate Patient Voices, and Experiences for Improved Decision Making Across the Lifecycle of a DrugUrsula Mann Andrew Spiegel, Esq. Lisa Machado Moderator:Farah Meghji
|
3:00 |
Afternoon Networking and Refreshment Break |
3:15 |
Weight Loss and GLP-1 Drugs: How to Manage Access and Reimbursement in An Evolving MarketBarbara A. Martinez Neda Nasseri Amine Mohammed Bouchaib Moderator:Tim Clarke There has been a steady shift in private payer market, with expanded coverage being offered for obesity management drugs, like smoking cessation drugs before it. Some GLP-1s or diabetes drugs are also being considered for use due their potential to promote weight loss. This raises questions important questions for our panelists to discuss; appropriate use, and whether access to these costly drugs will be sustainable moving forward, as demand grows. |
4:00 |
Where Patents Meet Market Access – Everything You Need to KnowFiona Legere This interactive session is tailored to cover everything your regulatory and market access team needs to know about pharmaceutical patents in Canada. Our presenters will help strengthen your understanding of how patents protect your company’s inventions and drug products:
|
4:45 |
Conference Adjourns |
Day 2 - Tuesday, February 13, 2024
8:00 |
Registration Opens & Continental Breakfast Served |
8:50 |
Opening Remarks from the Co-ChairsRosemarie Childerhose Dipti Tankala |
9:00 |
HOW SHOULD CANADA APPROACH NATIONAL PHARMACARE?Perspectives on Where We Go from Here: Models, Implementation, and Projected Outcomes for PatientChris Bonnett, MHSc, PhD The governing liberal party has committed to introducing pharmacare legislation as part of a confidence deal with the NDP. This follows analysis, discussion, and debates on whether a single payer system or a take a fill the gaps approach would be better for Canadians, the healthcare system, and the economy, but little in the way of a concrete plan for implementation. A recent report out from the parliamentary budgetary claims a single payer approach would cost over 30 billion but lead to economy-wide savings due to better price negotiations. It’s a critical time to revisit different perspectives on where we go from here, in terms of improving access to prescription drugs.
|
9:45 |
Canada’s Drug Shortage Task Team: Taking a Coordinated Approach to Prevent, Mitigate and Manage Supply Chain DisruptionsMina Tadrous Saad Ahmed, MD, CCFP(EM) Addressing drug shortages has been identified as a top priority for the Government of Canada. A multi stakeholder task team has been assembled to ensure patient access and prevent the detrimental impact of these shortages on the health of Canadians. This session will examine ongoing work by the task team, including:
|
10:30 |
Morning Coffee and Networking Break |
10:45 |
Biosimilars in Canada: Assessing Barriers, and Benchmarking with Early AdoptersJessica Arias Tijana Fazlagic Helen Stevenson Moderator:Rosemarie Childerhose
|
11:30 |
The Way Ahead for Cell and Gene Therapies: How to Create Healthcare System Infrastructure that Supports New Pathways to Access and ReimbursementSang Mi Lee Cell and gene therapy is an exciting and rapidly evolving area of development in the life sciences sector. These treatments can be life changing and potentially lifesaving for patients with rare diseases, and severe conditions. However, the cost of innovative treatments creates a challenge for the health system and requires new pathways to support access. Develop a strategic plan for your product and minimize hurdles with insights on:
|
12:15 |
Networking Lunch |
1:15 |
Accelerating DTx Market Access: Forecasting Future Regulatory and Reimbursement Pathways in CanadaAlexis Sciuk Mia Spiegelman Moderator:Ben King
|
2:15 |
Leveraging AI in Market Access: Examining Strategic Use Cases, Risks, and RegulationsJason Grier
|
2:45 |
Afternoon Networking Break |
3:00 |
Anticipating New Drug Pricing Guidance from the PMPRBDara Jospé Amendments to the Patented Medicines Price Review Board regulations came into force in July 2022, with an interim approach to price assessments in the absence of new guidelines to assist manufacturers in the prepare for the changes. After delays to the release of new guidelines a policy roundtable has been announced inviting stakeholders to share views on key themes intended to assist with the drafting process. This session will provide an overview of the latest developments to date on drug pricing in Canada and what manufacturers can expect moving into 2024. |
3:30 |
Examining Quebec’s Evolving Healthcare Landscape and the Potential Impact of Sweeping Changes Under Bill-15Patrick Manfred A proposed healthcare reform bill in Quebec is being hotly debated inside the legislature and fraught with controversy outside, as Quebecers consider the potential ramifications for everything from patient rights and access to medicines to language rights. The overarching proposal is to bring hospitals and university institutes under a crown corporation for a more centralized approach that achieves systemwide efficiencies in the delivery of care. Join this special focused session:
|
4:15 |
Conference Concludes |